Dj Coeptis Therapeutics Holdings Com, Inst Holders, 3Q 2025 (Coep)

The Rise of Multi-Dimensional Biotech

BRISTOL, TN, TN / ACCESS Newswire / October 14, 2025 / For decades, biotechnology investing was a binary game - a single trial failure could erase years of progress and billions in shareholder value. Yet a new generation of public life sciences companies is rewriting that equation by diversifying not just products, but business models.

Medicus Pharma Ltd. , Coeptis Therapeutics Holdings , and Quantum BioPharma Ltd. each represent a new archetype: the dual-engine biotech. They combine credible therapeutic innovation with a second, strategically differentiated platform - whether digital, diagnostic, or delivery-based - designed to create value independent of any single molecule.

Medicus Pharma: A Three-Track Clinical Portfolio Built for Risk Mitigation

Most biotech companies live or die on one program. Medicus Pharma is building three.

• Dermatology: Its lead program, Skinject, uses a dissolvable microneedle array to deliver doxorubicin directly to basal-cell carcinomas - a $9 billion market projected by 2034. FDA feedback confirmed the therapy qualifies for the expedited 505(b)(2) pathway, letting Medicus leverage existing safety data and shorten development timelines.

• Oncology / Urology: The Teverelix acquisition brought a next-generation GnRH antagonist that reduces cardiovascular risk for prostate-cancer patients. Meta-analyses show 40-50 percent fewer major cardiac events compared with legacy agonists.

• Vaccine Platform: A memorandum with HelixNano adds an exploratory third pillar - pairing Medicus's microneedle system with mRNA vaccine delivery.

By distributing development risk across three therapeutic areas - dermatology, oncology, and vaccines - Medicus positions itself to capture upside from multiple market verticals while reducing binary failure exposure.

Coeptis Therapeutics: Engineering an $800 Million Dual-Sector Enterprise

Coeptis Therapeutics has turned diversification into a valuation driver. SEC filings assign roughly $660 million to its core technology division and $75 million to a planned biotech spin-out - together forming an $835 million dual-sector framework.

• Life Sciences Division: The company develops advanced cell-therapy platforms, including DVX201 (allogeneic NK cell therapy) and SNAP-CAR, a universal multi-antigen CAR technology licensed from the University of Pittsburgh.

• Technology Division: Parallel to its clinical work, Coeptis acquired AI-driven marketing and robotic-automation software from NexGenAI Solutions Group - a strategic bridge between biotech operations and digital infrastructure.

That structural duality - combining wet-lab science with digital productivity - translates into operational leverage and potential tax efficiencies. The planned oncology spin-out, to be distributed 1:1 to shareholders, aligns management with long-term shareholder return, not just clinical milestones.

Quantum BioPharma: The Digitally Engineered Issuer

Quantum BioPharma stands at the frontier where biotechnology meets financial technology.

• Scientific Core: The Lucid-MS program targets remyelination and neuroprotection in multiple sclerosis through an innovative PET-imaging biomarker strategy with Massachusetts General Hospital.

• Consumer Health Arm: Via its subsidiary Celly Nu, Quantum earns a perpetual royalty stream from unbuzzd™, a clinically validated beverage that accelerates alcohol metabolism - providing non-dilutive recurring revenue.

• Digital Market Infrastructure: The company's dual listing on Upstream, a blockchain-enabled trading platform, gives it same-day settlement and global investor reach - a structural innovation few biotech peers can match.

Quantum embodies the concept of the programmable balance sheet - integrating science, liquidity, and data transparency into a cohesive corporate architecture.

The Common Thread: Structural Diversification as Shareholder Strategy

Each of these companies breaks from the single-asset biotech mold by embedding a secondary engine into its business model:

This hybridization is more than diversification. It's a shift toward anti-fragile biotech models - enterprises designed to create value whether through clinical success, digital scalability, or asset monetization.

The Institutional Takeaway

Investors increasingly reward companies that can demonstrate resilience across regulatory, technological, and capital cycles. Medicus, Coeptis, and Quantum are defining that playbook: pairing disciplined science with engineered optionality.

In a sector where binary outcomes have long dictated fortunes, these issuers are showing that the next generation of biotech isn't about a single cure - it's about constructing a balance sheet that can survive the wait for one.

Read more at The Vanderbilt Report

About Vanderbilt Report

Vanderbilt Report is a financial news and content platform. The information contained in this release is for informational purposes only and should not be considered an offer to buy or sell securities. All material is provided "as is" without any warranty of any kind.

Media Contact

Kristen Owens

info@vanderbiltreport.com

Compliance Note:

The Vanderbilt Report is a financial news and analysis platform. The information contained herein is based on publicly available filings and company disclosures believed to be accurate at the time of publication. This report is for informational purposes only and should not be construed as investment advice, a solicitation, or an offer to buy or sell any security.

The Vanderbilt Report does not provide investment banking, brokerage, or advisory services, and no compensation related to the analysis or publication has been received from the companies mentioned unless expressly disclosed.

Editorial Independence Disclosure:

One or more of the companies mentioned in this article may advertise on The Vanderbilt Report or its affiliated websites. Such advertising relationships are entirely independent of our editorial coverage and did not influence the preparation, analysis, or conclusions of this article.The Vanderbilt Report does not provide investment banking, brokerage, or advisory services, and no compensation related to the analysis or publication has been received from the companies mentioned unless expressly disclosed.

Readers are encouraged to perform their own due diligence and consult a licensed financial advisor before making any investment decisions. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

SOURCE: Vanderbilt Report

View the original press release on ACCESS Newswire

BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. today announced that The Vanderbilt Report has published coverage of the company following its recent SEC filings.

According to disclosures filed on January 31, 2025, Coeptis' technology division was assigned a $660.3 million fair market value. In addition, management has outlined a planned biotech spin-out, valued at approximately $75 million, together with tax advantages that may support future profitability.

The Vanderbilt Report reviewed these filings and highlighted a combined valuation framework of approximately $835 million, marking a milestone in Coeptis' transition from a pure biopharmaceutical operator to a dual-sector enterprise spanning both life sciences and advanced technology.

Why This Matters:

• Credible Benchmark: The $660M valuation stems directly from Coeptis' SEC disclosures.

• Biotech Spin-Out: Management intends to distribute oncology and cell therapy programs on a 1:1 basis to shareholders, with a proposed uplisting to Nasdaq.

• Independent Coverage: Vanderbilt Report has published analysis of these disclosures, underscoring the significance of the dual-sector model..

Read the full Vanderbilt Report analysis here

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company.

The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis' therapeutic portfolio includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing SNAP-CAR, a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside its GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and researchers at the Karolinska Institute.

Building on its core competencies, Coeptis has recently established a Technology Division, which includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group. These technologies are designed to optimize operations and enhance overall efficiency.

Headquartered in Wexford, PA, Coeptis is committed to advancing patient outcomes through innovation while operating under the highest standards of compliance and regulatory oversight. For more information, visit https://coeptistx.com.

Compliance Note: This announcement is based on Coeptis Therapeutics' SEC filings (10-Q, S-4, valuation disclosures) and public information. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT

Vanderbilt Report Media Relations

Kristen Owens

info@vanderbiltreport.com

SOURCE: Coeptis Therapeutics

View the original press release on ACCESS Newswire